Sildenafil citrate

Discontinued Product

Sildenafil citrate (Cat. No. 3784) has been withdrawn from sale for commercial reasons.
Cat.No. 3784 - Sildenafil citrate | C22H30N6O4S.C6H8O7 | CAS No. 171599-83-0
Description: Potent PDE5 inhibitor; orally active
Chemical Name: 1-[[3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate
Purity: ≥99% (HPLC)
Citations (1)
Literature (2)

Biological Activity for Sildenafil citrate

Orally active, potent inhibitor of phosphodiesterase 5 (PDE5) (IC50 = 4 nM). Enhances nitric oxide-dependent relaxation of human corpus cavernosum in vitro. Promotes mobilization of hematopoietic stem cells (HSCs) in combination with AMD 3100 (Cat. No. 3299). Reduces pulmonary pressure and edema.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Compound Libraries for Sildenafil citrate

Sildenafil citrate is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Sildenafil citrate

M. Wt 666.7
Formula C22H30N6O4S.C6H8O7
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 171599-83-0
PubChem ID 62853
Smiles O=C(O)C(O)(CC(O)=O)CC(O)=O.CN1CCN(S(C2=CC=C(OCC)C(C(NC4=C3N(C)N=C4CCC)=NC3=O)=C2)(=O)=O)CC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Sildenafil citrate

Certificate of Analysis / Product Datasheet
Select another batch:

References for Sildenafil citrate

References are publications that support the biological activity of the product.

Ballard et al (1998) Effects of silde. on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J.Urol. 159 2164 PMID: 9598563

Turko et al (1999) Inhibition of cyclic cGMP-binding cyclic GMP-specific phosphodiesterase (type 5) by silde. and related compounds. Mol.Pharmacol. 56 124 PMID: 10385692

Ghofrani et al (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat.Rev.Drug Discov. 5 689 PMID: 16883306

Smith-Berdan et al (2019) Viagra enables efficient, single-day hematopoietic stem cell mobilization. Stem Cell Reports. PMID: 31607567

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: Sildenafil citrate, Sildenafil citrate supplier, phosphodiesterases, 5, PDE5, inhibitors, inhibits, orally, active, potent, Pfizer, HSC, hematopoietic, haematopoietic, stem, cells, mobilization, COVID-19, pulmonary, edema, Phosphodiesterases, Stem, Cell, Proliferation, 3784, Tocris Bioscience

1 Citation for Sildenafil citrate

Citations are publications that use Tocris products. Selected citations for Sildenafil citrate include:

Vandendriessche et al (2013) The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. Development 8 e72155 PMID: 24015214

Reviews for Sildenafil citrate

There are currently no reviews for this product. Be the first to review Sildenafil citrate and earn rewards!

Have you used Sildenafil citrate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.